Immunomedics, Inc. (NASDAQ:IMMU) Files An 8-K Other Events
Item8.01. Other events
On February 23, 2017, Immunomedics, Inc. issued a press release
titled Immunomedics Announces Companys Immune Checkpoint
Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting
Bispecific Antibodies. The full text of the press release is
attached to this current report on Form8-K as Exhibit99.1 and is
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description of Exhibit |
|
| 99.1 |
Press Release of Immunomedics, Inc., dated February 23, 2017, titled Immunomedics Announces Companys Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies |
About Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information
Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session down -0.06 at 4.90 with 1,878,728 shares trading hands.
